High dose Losartan and ACE gene polymorphism in IgA nephritis
| Autor: | Hui Lin Choong, Grace S L Lee, Han-Kim Tan, Seng-Hoe Tan, Lim Ch, Hwee-Boon Tan, Stephanie Fook-Chong, Marjorie Foo, Zhao Yi, Keng-Thye Woo, Gilbert S.C. Chiang, C. C. Tan, Anantharaman Vathsala, Kok-Seng Wong, Choong-Meng Chan, Evan J.C. Lee |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Ace gene polymorphism
medicine.medical_specialty Proteinuria business.industry Urology Renal function Ace gene Pharmacology urologic and male genital diseases medicine.disease Molecular medicine female genital diseases and pregnancy complications Losartan Genetics Medicine Genetics(clinical) cardiovascular diseases medicine.symptom business Renal survival Nephritis hormones hormone substitutes and hormone antagonists Genetics (clinical) Research Article medicine.drug |
| Zdroj: | Genomic Medicine. 2:83-91 |
| ISSN: | 1871-7942 1871-7934 |
| Popis: | Background/aimsSeveral studies have reported varying results of the influence of ACE gene on ACEI/ARB therapy. The efficacy of high dose ARB and its influence on ACE gene have not been explored. This is a 6 year randomised trial in IgA nephritis comparing high dose ARB (Losartan 200 mg/day) with normal dose ARB (Losartan 100 mg/day), normal dose ACEI (20 mg/day) and low dose ACEI (10 mg/day).ResultsPatients on high dose ARB had significantly lower proteinuria, 1.0 ± 0.8 gm/day compared to 1.7 ± 1.0 g/day in the other groups (P = 0.0005). The loss in eGFR was 0.7 ml min−1year−1for high dose ARB compared to 3.2–3.5 ml min−1year−1for the other three groups (P = 0.0005). There were more patients on high dose ARB with improvement in eGFR compared to other three groups (P P P = 0.037).ConclusionHigh dose ARB is more efficacious in reducing proteinuria and preserving renal function when compared with normal dose ARB and ACEI, and also obviates the genomic influence of ACE gene polymorphism on renal survival. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink